CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Biological/Vaccine: Angiotensin peptide (1-7) derived plasmaWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug75 ARALAST NP Wiki 1.00

Correlated MeSH Terms (5)


Name (Synonyms) Correlation
D019896 Alpha 1-Antitrypsin Deficiency NIH 1.00
D004646 Emphysema NIH 0.71
D029424 Pulmonary Disease, Chronic Obstructive NIH 0.35
D008173 Lung Diseases, Obstructive NIH 0.33
D008171 Lung Diseases, NIH 0.26

Correlated HPO Terms (3)


Name (Synonyms) Correlation
HP:0006510 Chronic pulmonary obstruction HPO 0.35
HP:0006536 Pulmonary obstruction HPO 0.33
HP:0002088 Abnormal lung morphology HPO 0.26

There is one clinical trial.

Clinical Trials


1 Evaluation of the Possible Role of Angiotensin Peptide (1-7) on Treatment of COVID-19

Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.

NCT04375124 COVID-19 Biological: Biological/Vaccine: Angiotensin peptide (1-7) derived plasma

Primary Outcomes

Description: mortality rates in two groups will be compared

Measure: mortality

Time: 4 months


No related HPO nodes (Using clinical trials)